Samuraciclib - Carrick Therapeutics
Alternative Names: CT-7001; ICEC-0942Latest Information Update: 14 Jul 2024
At a glance
- Originator Imperial College of Science, Technology and Medicine
- Developer Carrick Therapeutics; Menarini; Pfizer
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Benzylamines; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II HER2 negative breast cancer
- Phase I/II Solid tumours
- No development reported Acute myeloid leukaemia; Breast cancer; Small cell lung cancer
Most Recent Events
- 14 Jul 2024 3862712- Missing location added, Abstract contains trial design hence not covered
- 10 Jan 2024 Pfizer initiated the phase Ib/II TACTIVE-U trial for HER-2 negative breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06125522)
- 27 Nov 2023 Phase-II clinical trials in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in Turkey, Spain (PO) (NCT05963984) (EudraCT2023-503903-27-00)